Faculty Disclosures
| Morris Cohen |
Morris Cohen has received research support from Stanford University. Morris Cohen has received publishing royalties from a publication relating to health care. |
| Marissa Kellogg, MD, MPH, FAAN |
The institution of Dr. Kellogg has received research support from VA & DoD. |
| Tia Kowal |
Tia Kowal has received personal compensation for serving as an employee of Neurona Tharapeutics. Tia Kowal has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist with Neurona Theraputics. |
| Linda S. Williams, MD, FAAN |
The institution of Dr. Williams has received research support from VA HSR&D. |
| Seonok Lee |
Seonok Lee has received personal compensation for serving as an employee of Neurona Therapeutics. |
| Paula E. Voinescu, MD |
The institution of Dr. Voinescu has received research support from Epilepsy Foundation of New England. The institution of Dr. Voinescu has received research support from BWH - Connors Center. The institution of an immediate family member of Dr. Voinescu has received research support from American Epilepsy Society. Dr. Voinescu has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Phillipines League Against Epilepsy. Dr. Voinescu has received personal compensation in the range of $500-$4,999 for serving as a PhD Opponent with University of Bergen, Norway. Dr. Voinescu has a non-compensated relationship as a Board Member and Chair with My Epilepsy Story that is relevant to AAN interests or activities. Dr. Voinescu has a non-compensated relationship as a Speaker with Epilepsy Foundation that is relevant to AAN interests or activities. Dr. Voinescu has a non-compensated relationship as a Grant Reviewer with American Epilepsy Society that is relevant to AAN interests or activities. Dr. Voinescu has a non-compensated relationship as a Member of Scientific Advisory Committee with North American AED Pregnancy Registry that is relevant to AAN interests or activities. |
|
No disclosure on file
|
| Heather Robinson |
No disclosure on file
|
| Kim Burchiel |
Kim Burchiel has nothing to disclose. |
| Robert Niecestro |
No disclosure on file
|
| Luis Fuentealba |
Luis Fuentealba has nothing to disclose. |
| Christopher Kenney |
No disclosure on file
|
| Angela K. Birnbaum, PhD |
The institution of Dr. Birnbaum has received research support from National Institutes of Health. The institution of Dr. Birnbaum has received research support from Randy Shaver Cancer and Research Foundation. Dr. Birnbaum has received intellectual property interests from a discovery or technology relating to health care. |
| Carrie Brown |
No disclosure on file
|
| Robert Beach, MD, PhD, FAAN |
The institution of Dr. Beach has received research support from Neurona. |
| Sheri Madrid |
Mrs. Madrid has nothing to disclose. |
| Sergei Shevchuk |
Sergei Shevchuk has received personal compensation for serving as an employee of Neurona Therapeutics. |
| Piero Perucca, MD |
The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Perucca has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. The institution of Dr. Perucca has received research support from NHMRC. The institution of Dr. Perucca has received research support from Epilepsy Foundation. The institution of Dr. Perucca has received research support from Monash University. The institution of Dr. Perucca has received research support from Sanming Project Grant, Shenzhen government. The institution of Dr. Perucca has received research support from Medical Research Future Fund. The institution of Dr. Perucca has received research support from Norman Beischer Medical Research Foundation. The institution of Dr. Perucca has received research support from NHMRC. The institution of Dr. Perucca has received research support from Austin Medical Research Foundation. The institution of Dr. Perucca has received research support from The University of Melbourne and The University of Bonn. The institution of Dr. Perucca has received research support from Austin Medical Research Foundation . Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Eisai. Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving as a Speaker with UCB. Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving as a Speaker with LivaNova. Dr. Perucca has a non-compensated relationship as a Member, Central Project Commission with EURAP-International Registry of Antiepileptic Drugs and Pregnancy that is relevant to AAN interests or activities. Dr. Perucca has a non-compensated relationship as a Member, Advisory Board with Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs that is relevant to AAN interests or activities. |
| Emma Foster, MD, MBBS |
The institution of Dr. Foster has received research support from Monash University Bridging Postdoctoral Fellowship. The institution of Dr. Foster has received research support from Sylvia and Charles Viertel Charitable Foundation. The institution of Dr. Foster has received research support from Brain Foundation (Australia). The institution of Dr. Foster has received research support from Australian Epilepsy Research Fund. The institution of Dr. Foster has received research support from LivaNova. The institution of Dr. Foster has received research support from Lundbeck Australia. |
| Stephanie Chamorro |
No disclosure on file
|
| Victoria Hosford |
No disclosure on file
|
| Sean Sean |
No disclosure on file
|
| Andrea Carmack |
No disclosure on file
|
| Kimford J. Meador, MD, FAAN |
The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from The Epilepsy Consortium. |
| Ian Stewart |
No disclosure on file
|
| Zulfi Haneef, MD, MBBS, MRCP, FAAN |
Dr. Haneef has received publishing royalties from a publication relating to health care. |
| Elizabeth Gerard, MD |
Dr. Gerard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. The institution of Dr. Gerard has received research support from NIH/NINDS. The institution of Dr. Gerard has received research support from Xenon Pharmaceuticals. The institution of an immediate family member of Dr. Gerard has received research support from NIH. The institution of Dr. Gerard has received research support from Eisai, Inc. (via Stanford University). Dr. Gerard has received publishing royalties from a publication relating to health care. |
| Alain Z. Lekoubou Looti, MD |
Dr. Lekoubou Looti has nothing to disclose. |
| David C. Spencer, MD, FAAN |
Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuiticals. Dr. Spencer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace Inc. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various. The institution of Dr. Spencer has received research support from NIH. Dr. Spencer has received publishing royalties from a publication relating to health care. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Faculty in Teaching Course supported by unrestricted educational grants with Creative 好色先生 Concepts. |
| Holly Finefrock |
Ms. Finefrock has received personal compensation for serving as an employee of Neurona Therapeutics. |
| Mark R. Keezer, MD, PhD |
The institution of Dr. Keezer has received research support from TD Bank. The institution of Dr. Keezer has received research support from Savoy Foundation. The institution of Dr. Keezer has received research support from Canadian Institutes of Health Research. The institution of Dr. Keezer has received research support from Fonds de Recherche Québec Santé. The institution of Dr. Keezer has received research support from Canadian Institutes of Health Research. The institution of Dr. Keezer has received research support from Precision Child Health Partnership Catalyst Program. |
| Saul Mullen |
No disclosure on file
|
| Yves Maury |
Yves Maury has received personal compensation for serving as an employee of Neurona Therapeutics. Yves Maury has stock in Neurona therapeutics. |
| Jale Agaoglu, MD |
No disclosure on file
|
| Matthew W. Luedke, MD |
Dr. Luedke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aucta Pharmaceuticals. Dr. Luedke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Luedke has received personal compensation in the range of $0-$499 for serving as a Consultant for Alphasights . Dr. Luedke has received personal compensation in the range of $0-$499 for serving as a Consultant for Clarivate. Dr. Luedke has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Starnes Davis Florie LLP. Dr. Luedke has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Huff Powell Bailey. The institution of Dr. Luedke has received research support from US NAVY. The institution of Dr. Luedke has received research support from Neurona. The institution of Dr. Luedke has received research support from Xenon. |
| Brittany Walsh |
No disclosure on file
|
| Erin C. Conrad, MD |
Dr. Conrad has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. Dr. Conrad has stock in Humana. Dr. Conrad has stock in Lilly Eli. Dr. Conrad has stock in Medtronic. Dr. Conrad has stock in Merck. Dr. Conrad has stock in Nevro. Dr. Conrad has stock in Sanofi. Dr. Conrad has stock in United Health Group. |
| Kiril Shevchuk |
No disclosure on file
|
| Harish Babu |
Harish Babu has nothing to disclose. |
| Cynthia L. Harden, MD |
Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc.. Dr. Harden has received intellectual property interests from a discovery or technology relating to health care. |
| Jerry J. Shih, MD, FAAN |
Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Life. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Shih has received research support from Neurona. The institution of Dr. Shih has received research support from NCGS, Inc. Dr. Shih has a non-compensated relationship as a Test Writing Committee Member with ABPN that is relevant to AAN interests or activities. |
| Constanza Luzon |
Constanza Luzon has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals. |
| Alice Henning |
No disclosure on file
|
| Rebecca Wharrie |
No disclosure on file
|
| Catherine Priest, PhD |
Catherine Priest has received personal compensation for serving as an employee of Neurona Therapeutics. Catherine Priest has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Catherine Priest has received research support from CIRM. |
| Roland Thijs |
No disclosure on file
|
| Chelsea Robalino |
No disclosure on file
|
| Mary Jo Pugh, PhD, RN, FAAN |
The institution of Dr. Pugh has received research support from Department of Defense, Epilepsy Research Program. The institution of Dr. Pugh has received research support from VA Health Services Research and Development Service. The institution of Dr. Pugh has received research support from VA Rehabilitation Research and Development Service. The institution of Dr. Pugh has received research support from Congressionally Directed Research Programs. |
| Rebecca O'Dwyer, MD |
Dr. O'Dwyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. O'Dwyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Sciences. |
| David E. Blum, MD |
Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics. |
| Jacqueline Hirschey, MD |
Dr. Hirschey has nothing to disclose. |
| Nathan Shlobin |
No disclosure on file
|
| Sepehr Sani |
The institution of Sepehr Sani has received research support from NIH. Sepehr Sani has received intellectual property interests from a discovery or technology relating to health care. Sepehr Sani has received publishing royalties from a publication relating to health care. |
| Jack Germaine |
No disclosure on file
|
| Marina Bershteyn |
Marina Bershteyn has received personal compensation for serving as an employee of Neurona therapeutics. Marina Bershteyn has stock in Neurona therapeutics. Marina Bershteyn has received intellectual property interests from a discovery or technology relating to health care. |
| Sonja Kriks |
Sonja Kriks has received personal compensation for serving as an employee of Neurona Therapeutics. Sonja Kriks has stock in Neurona Therapeutics. Sonja Kriks has received intellectual property interests from a discovery or technology relating to health care. |
| Jacqueline French, MD, FAAN |
Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation. The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB). The institution of Dr. French has received research support from GW/One8 Foundation/FACES. The institution of Dr. French has received research support from NINDS. The institution of Dr. French has received research support from Xenon. The institution of Dr. French has received research support from Cerevel. The institution of Dr. French has received research support from FACES. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Epilepsy Study Consortium. The institution of Dr. French has received research support from UCB. The institution of Dr. French has received research support from Praxis. Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Acadia Pharmaceuticals Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Access Industries that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Acuta Capital Partners LLC that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with AFASCI Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Agrithera, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Alkermes that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Angelini Pharma S.p.A. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Axonis Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bain Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Beacon Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Biohaven Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Bloom Science, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bright Minds Biosciences, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Capsidia Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Cerebral Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerecin, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, SAB with Cognizance Biomarkers that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ceribell that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cowen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with EcoR1 Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EG 427 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant, Advisory Board with Eisai that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant/Advisory Board with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EpiMinder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Harmony that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board with Ionis Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with iQure Pharma, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with IQVIA that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Janssen Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Jazz Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Leal Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, with Livanova that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with London Research & Pharmaceuticals that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Longboard Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Maplight Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Marinus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Medscape/Web MD that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Modulight Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Montara Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mosaica Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neumarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Neumirna Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurelis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Neurocrine that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuroPro Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neuroventis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neurona Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Neuvarti that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Noema that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ono Pharmaceutical that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board with Otsuka that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board with Ovid Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LYT Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with QurAlis Corp that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Rapport Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Receptor Holdings, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Rivervest Venture Partners that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Sage Therapeutics, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with SK Life Science that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stoke that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Stream Neuroscience that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Takeda that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Taysha Gene Therapies that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with UCB, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with uniQure that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Ventus Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Vida Ventures Management that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Xenon Pharmaceuticals that is relevant to AAN interests or activities. |
| David W. Loring, PhD, FAAN |
Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE. The institution of Dr. Loring has received research support from NIH. Dr. Loring has received publishing royalties from a publication relating to health care. |
| Jenny Qian |
Jenny Qian has nothing to disclose. |
| Austin Cohrs |
No disclosure on file
|
| Derek Southwell |
Derek Southwell has nothing to disclose. |
| Ji-Hye Jung |
Ji-Hye Jung has nothing to disclose. |
| Gautam Banik |
Gautam Banik has received personal compensation for serving as an employee of Neurona Therapeutics. |
| Sharona Ben-Haim |
No disclosure on file
|
| Michael Chen |
No disclosure on file
|
| Alison M. Pack, MD, FAAN |
An immediate family member of Dr. Pack has received personal compensation for serving as an employee of REGENEXBIO. The institution of Dr. Pack has received research support from National Institutes of Health. Dr. Pack has received publishing royalties from a publication relating to health care. |
| Babak Razavi, MD, PhD |
Dr. Razavi has stock in CortexXus. The institution of Dr. Razavi has received research support from Neuropace. |
| Martin Brodie |
Martin Brodie has nothing to disclose. |
| Brianna Feld |
Brianna Feld has received personal compensation for serving as an employee of Neurona Therapeutics. |
| Abigail Matthews |
No disclosure on file
|
| Kimberley Irwin |
No disclosure on file
|
| Brin Freund, MD |
Dr. Freund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Freund has received research support from Mayo Clinic. |
| Darwin Amir, MD, FAAN |
No disclosure on file
|
| Manaz Rezayee |
Ms. Rezayee has nothing to disclose. |
| Laura A. Kalayjian, MD |
The institution of Dr. Kalayjian has received research support from NIH. |
| Roger J. Porter, MD, FAAN |
Dr. Porter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Longboard. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engrail. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axonis. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bright MInds Bioscience. Dr. Porter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Autobah. Dr. Porter has received publishing royalties from a publication relating to health care. |
| Lyn Millist |
No disclosure on file
|
| Caitlin Roberts |
No disclosure on file
|
| Page B. Pennell, MD, FAAN |
The institution of Dr. Pennell has received research support from NIH. |
| John D. Hixson, MD |
Dr. Hixson has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Hixson has received personal compensation for serving as an employee of Nile Ai. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NextSense Inc.. Dr. Hixson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seer Medical. Dr. Hixson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Expert Institute. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Reviewer with Epilepsy Study Consortium. |
| Terence J. O'Brien, MD |
The institution of Prof. O'Brien has received research support from Eisai. The institution of Prof. O'Brien has received research support from UCB. The institution of Prof. O'Brien has received research support from BioGen. The institution of Prof. O'Brien has received research support from ES Theraputics. The institution of an immediate family member of Prof. O'Brien has received research support from Epidarex. |
| Alessandro Bulfone, MD |
Dr. Bulfone has received personal compensation for serving as an employee of Neurona Therapeutics Inc. |
| Eamonn Kennedy |
No disclosure on file
|
| David C. Reutens, MD |
The institution of Dr. Reutens has received research support from Australian Research Council. The institution of Dr. Reutens has received research support from Siemens Health Care. The institution of Dr. Reutens has received research support from Vivazone Pty Ltd. Dr. Reutens has received intellectual property interests from a discovery or technology relating to health care. |
| Rose Larios, PhD |
Dr. Larios has received personal compensation for serving as an employee of Neurona Therapeutics. |
| John-Paul Nicolo, MBBS |
Dr. Nicolo has nothing to disclose. |
| Michael A. Rogawski, MD, PhD |
Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals. |
| Jimmy Li, MD |
Dr. Li has received research support from Fonds de recherche du Québec - Santé. |
| Charles Deacon, MD |
Dr. Deacon has nothing to disclose. |
| Emilio Perucca |
Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SKB Life Sciences. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon Pharma. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRIN Therapeutics. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sun Pharma. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Emilio Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Xenon Pharma. Emilio Perucca has received publishing royalties from a publication relating to health care. Emilio Perucca has received publishing royalties from a publication relating to health care. |
| Megan Amuan |
No disclosure on file
|
| Fenny L. Yudiarto, MD, PhD, FAAN |
Dr. Yudiarto has nothing to disclose. |
| Elisabeth Wilde |
Elisabeth Wilde has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neuropsychology. The institution of Elisabeth Wilde has received research support from CDMRP/DoD. The institution of Elisabeth Wilde has received research support from VA. The institution of Elisabeth Wilde has received research support from NIH. The institution of Elisabeth Wilde has received research support from Cohen Veteran Biosciences. |
| Gregory N. Beatch, PhD |
Dr. Beatch has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc. Dr. Beatch has stock in Xenon Pharmaceuticals Inc. Dr. Beatch has received intellectual property interests from a discovery or technology relating to health care. |
| Cory R. Nicholas, PhD |
Dr. Nicholas has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Nicholas has stock in Neurona Therapeutics. Dr. Nicholas has received intellectual property interests from a discovery or technology relating to health care. |